Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 477

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 477
---
 by the independent registered public
    accounting firm; and

    ●
    assisting
    our board of directors in monitoring the performance of our internal audit function.

Our
audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards
of Nasdaq, a copy of which will be available on our website at www.telomirpharma.com.

Compensation
Committee

The
Compensation Committee was initially established upon the effectiveness of our initial public offering on February 9, 2024. As of December
2024, the Compensation Committee consists of Dr. Matthew P. Del Giudice (Chair), and Mr. Edward MacPherson. Dr. Matthew P. Del Giudice
succeeded Talhia Tuck as Chair of the Compensation Committee following her resignation, along with Bradley Kroenig, from the Board of
Directors in August 2024. Each member of the committee meets the requirements for independence under the listing standards of Nasdaq
and SEC rules and regulations. Each member is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange
Act, or Rule 16b-3.

In
arriving at these determinations, our board of directors examined all factors relevant to determining whether any compensation committee
member had a relationship to us that is material to that member’s ability to be independent from management in connection with
carrying out such member’s duties as a compensation committee member. 

The
compensation committee’s main purpose is to review and recommend policies relating to compensation and benefits of our officers
and employees. Our compensation committee is responsible for, among other things:

    ●
    reviewing,
    approving, and determining, or making recommendations to our board of directors regarding, the compensation and compensation arrangements
    of our executive officers;

    ●
    administering
    our equity compensation plans;

    ●
    reviewing
    and approving, or making recommendations to our board of directors regarding, incentive compensation and equity compensation plans;
    and

    ●
    establishing
    and reviewing general policies relating to compensation and benefits of our employees.

Our
compensation committee will operate under a written charter that satisfies the applicable rules and regulations of the SEC and the listing
standards of Nasdaq, a copy of which will be available on our website.

59

Nominating
and Corporate Governance Committee

The
nominating and corporate governance committee was established upon